Phosphate: Known and potential roles during development and regeneration of teeth and supporting structures

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 84, Issue 4, 2008, Pages 281-314

  Foster, Brian L ^a   Tompkins, Kevin A ^a   Rutherford, R Bruce ^a   Zhang, Hai ^a   Chu, Emily Y ^a   Fong, Hanson ^b   Somerman, Martha J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

Author keywords

Cementum; Dentin; Fibroblast growth factor 23; Periodontal ligament; PHEX; Phosphate metabolism; Progressive ankylosis protein; Tissue nonspecific alkaline phosphatase; Tooth development; Tooth root

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCERAMICS; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM ION; CALCIUM PHOSPHATE; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; GLYCOPROTEIN; IBANDRONIC ACID; KLOTHO PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATASE; PHOSPHATE; PHOSPHODIESTERASE I; POLYPHOSPHATE; PROGRESSIVE ANKYLOSIS PROTEIN; PROTEIN; PROTEINASE; PYROPHOSPHATE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE MINERALIZATION; DRUG SUBSTITUTION; ENDOCRINE SYSTEM; FRACTURE; FRAGILITY FRACTURE; GENE; GENE MUTATION; HOMEOSTASIS; HORMONE ACTION; ION TRANSPORT; MINERALIZATION; MOUTH CAVITY; OSSIFICATION; OSTEOCLAST; PAGET BONE DISEASE; PHENOTYPE; PHOSPHATE METABOLISM; PHOSPHATE REGULATING GENE; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; REGENERATION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TOOTH; TOOTH DEVELOPMENT; X CHROMOSOME;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; HUMANS; PHOSPHATES; REGENERATION; TOOTH;

MUS;

EID: 57649219112     PISSN: 1542975X     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrc.20136     Document Type: Review

References (387)

1. Abe K, Ooshima T, Lily TS, et al. 1988. Structural deformities of deciduous teeth in patients with hypophosphatemic vitamin D-resistant rickets. Oral Surg Oral Med Oral Pathol 65:191-198.
2. Abe K, Ooshima T, Masatomi Y, et al. 1989. Microscopic and crystallographic examinations of the teeth of the X-linked hypophosphatemic mouse. J Dent Res 68:1519-1524.
3. Abe K, Masatomi Y, Nakajima Y, et al. 1992. The occurrence of interglobular dentin in incisors of hypophosphatemic mice fed a high-calcium and high-phosphate diet. J Dent Res 71:478-483.
4. Adams CS, Mansfield K, Perlot RL, et al. 2001. Matrix regulation of skeletal cell apoptosis. Role of calcium and phosphate ions. J Biol Chem 276:20316-20322.
5. Addison W, Nakano Y, Loisel T, et al. 2008. MEPE-ASARM Peptides control extracellular matrix mineralization by binding to hydroxyapatite - an inhibition regulated by PHEX Cleavage of ASARM. J Bone Miner Res 23:1638-1649.
6. Addison WN, Azari F, Sorensen ES, et al. 2007. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282:15872-15883.
7. ADHR Consortium. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348.
8. Akintoye SO, Lee JS, Feimster T, et al. 2003. Dental characteristics of fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96:275-282.
9. Akintoye SO, Otis LL, Atkinson JC, et al. 2004. Analyses of variable panoramic radiographic characteristics of maxillo-mandibular fibrous dysplasia in McCune-Albright syndrome. Oral Dis 10:36-43.
10. Anderson HC, Harmey D, Camacho NP, et al. 2005. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 166:1711-1720.
11. Araya K, Fukumoto S, Backenroth R, et al. 2005. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523-5527.
12. Argiro L, Desbarats M, Glorieux FH, et al. 2001. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74:342-351.
13. Baroncelli GI, Angiolini M, Ninni E, et al. 2006. Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets. Eur J Paediatr Dent 7:61-66.
14. Barrere F, van der Valk CM, Dalmeijer RA, et al. 2003a. Osteogenecity of octacalcium phosphate coatings applied on porous metal implants. J Biomed Mater Res A 66:779-788.
15. Barrere F, van der Valk CM, Meijer G, et al. 2003b. Osteointegration of biomimetic apatite coating applied onto dense and porous metal implants in femurs of goats. J Biomed Mater Res B Appl Biomater 67:655-665.
16. Barrere F, van Blitterswijk CA, de Groot K. 2006. Bone regeneration: molecular and cellular interactions with calcium phosphate ceramics. Int J Nanomedicine 1:317-332.
17. Barthel TK, Mathern DR, Whitfield GK, et al. 2007. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 103:381-388.
18. Bartold PM, McCulloch CA, Narayanan AS, et al. 2000. Tissue engineering: a new paradigm for periodontal regeneration based on molecular and cell biology. Periodontology 2000 24:253-269.
19. Bartold PM, Shi S, Gronthos S. 2006a. Stem cells and periodontal regeneration. Periodontology 2000 40:164-172.
20. Bartold PM, Xiao Y, Lyngstaadas SP, et al. 2006b. Principles and applications of cell delivery systems for periodontal regeneration. Periodontology 2000 41:123-135.
21. Beck GR Jr. 2003. Inorganic phosphate as a signaling molecule in osteoblast differentiation. J Cell Biochem 90:234-243.
22. Beck GR Jr, Knecht N. 2003. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J Biol Chem 278:41921-41929.
23. Beck GR Jr, Moran E, Knecht N. 2003. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. Exp Cell Res 288:288-300.
24. Beck GR Jr, Sullivan EC, Moran E, et al. 1998. Relationship between alkaline phosphatase levels, osteopontin expression, and mineralization in differentiating MC3T3-E1 osteoblasts. J Cell Biochem 68:269-280.
25. Beck GR Jr, Zerler B, Moran E. 2000. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci USA 97:8352-8357.
26. Beertsen W, VandenBos T, Everts V. 1999. Root development in mice lacking functional tissue non-specific alkaline phosphatase gene: inhibition of acellular cementum formation [In Process Citation]. J Dent Res 78:1221-1229.
27. Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. 2004. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-462.
28. Berdal A, Gorter de Vries I, Hotton D, et al. 1991. The cellular and extracellular distribution of osteocalcin and dentin phosphoprotein in teeth of vitamin D-deficient rats. J Biol Buccale 19:45-53.
29. Berdal A, Papagerakis P, Hotton D, et al. 1995. Ameloblasts and odontoblasts, target-cells for 1,25-dihydroxyvitamin D3: a review. Int J Dev Biol 39:257-262.
30. Berndt T, Kumar R. 2007. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 69:341-359.
31. Berndt T, Craig TA, Bowe AE, et al. 2003. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785-794.
32. Berndt TJ, Schiavi S, Kumar R. 2005. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170-F1182.
33. Berndt TJ, Bielesz B, Craig TA, et al. 2006. Secreted frizzled-related protein-4 reduces sodium-phosphate cotransporter abundance and activity in proximal tubule cells. Pflugers Arch 451:579-587.
34. Bertoldo F, Santini D, Lo Cascio V. 2007. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4:711-721.
35. Bielesz B. 2006. Emerging role of a phosphatonin in mineral homeostasis and its derangements. Eur J Clin Invest 36(Suppl 2):34-42.
36. Blethen FA, Chu EY, Foster BL, Tompkins KA, Sitara D, Lanske B, et al. 2008. The effect of mutations in the systemic phosphate regulating gene Fgf-23 on the dentoalveolar complex. AAE Annual Session, Vancouver, Canada.
37. Boonen S, Laan RF, Barton IP, et al. 2005. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291-1298.
38. Bouillon R, Okamura WH, Norman AW. 1995. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16:200-257.
39. Boukpessi T, Septier D, Bagga S, et al. 2006. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int 79:294-300.
40. Boyden LM, Mao J, Belsky J, et al. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
41. Broadus AE. 2003. Mineral balance and homeostasis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorder of mineral metabolism. 5th ed. Washington DC: ASBMR. pp. 105-111.
42. Brockman H. 1936. Die Isolierung des antirachitischen Vitamins aus Thunfischleberol. Hoppe Seylers Z Physiol Chem 241:104-115.
43. Bronckers AL, Price PA, Schrijvers A, et al. 1998. Studies of osteocalcin function in dentin formation in rodent teeth. Eur J Oral Sci 106:795-807.
44. Brown AJ, Zhong M, Finch J, et al. 1995. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 136:1419-1425.
45. Bruckner RJ, Rickles NH, Porter DR. 1962. Hypophosphatasia with premature shedding of teeth and aplasia of cementum. Oral Surg Oral Med Oral Pathol 15:1351-1369.
46. Caffesse RG, de la Rosa M, Mota LF. 2002. Regeneration of soft and hard tissue periodontal defects. Am J Dent 15:339-345.
47. Calvi LM, Shin HI, Knight MC, et al. 2004. Constitutively active PTH/PTHrP receptor in odontoblasts alters odontoblast and ameloblast function and maturation. Mech Dev 121:397-408.
48. Campos M, Couture C, Hirata IY, et al. 2003. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 373(Part 1):271-279.
49. Capuano P, Radanovic T, Wagner CA, et al. 2005. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor-and 1alphaOHase-deficient mice. Am J Physiol Cell Physiol 288:C429-C434.
50. Carpenter TO, Ellis BK, Insogna KL, et al. 2005. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012-1020.
51. Chang PL, Prince CW. 1993. 1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate-induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells. Cancer Res 53(10 Suppl):2217-2220.
52. Chapple IL. 1993. Hypophosphatasia: dental aspects and mode of inheritance. J Clin Periodontol 20:615-622.
53. Chaussain-Miller C, Sinding C, Septier D, et al. 2007. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis 13:482-489.
54. Chesnut CH. 2006. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Drugs 66:1351-1359.
55. Chu EY, Foster BL, Swanson EC, Rutherford RB, Sitara D, Lanske BKM, et al. 2007. Local and systemic regulation of tooth root tissues. 85th General Session of IADR/AADR/CADR, New Orleans, LA.
56. Cobourne MT, Sharpe PT. 2003. Tooth and jaw: molecular mechanisms of patterning in the first branchial arch. Arch Oral Biol 48:1-14.
57. Cohen S, Becker GL. 1976. Origin, diagnosis, and treatment of the dental manifestations of vitamin D-resistant rickets: review of the literature and report of case. J Am Dent Assoc 92:120-129.
58. Coleman RE. 2005. Bisphosphonates in breast cancer. Ann Oncol 16:687-695.
59. Cooke NE, Haddad JG. 1989. Vitamin D binding protein (Gc-globulin). Endocr Rev 10:294-307.
60. Croom KF, Scott LJ. 2006. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 66:1593-1601; discussion 1602-1593.
61. D'Errico JA, Berry JE, Ouyang H, et al. 2000. Employing a transgenic animal model to obtain cementoblasts in vitro. J Periodontol 71:63-72.
62. Dardenne O, Prud'homme J, Arabian A, et al. 2001. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin Ddeficiency rickets. Endocrinology 142:3135-3141.
63. Dassule HR, Lewis P, Bei M, et al. 2000. Sonic hedgehog regulates growth and morphogenesis of the tooth. Development 127:4775-4785.
64. de Groot K, Geesink R, Klein CP, et al. 1987. Plasma sprayed coatings of hydroxylapatite. J Biomed Mater Res 21:1375-1381.
65. de Jonge LT, Leeuwenburgh SC, Wolke JG, et al. 2008. Organic-inorganic surface modifications for titanium implant surfaces. Pharm Res 25:2357-2369.
66. Delmas PD, Meunier PJ. 1997. The management of Paget's disease of bone. N Engl J Med 336:558-566.
67. Devogelaer JP. 2000. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 12:331-335.
68. Doi Y, Iwanaga H, Shibutani T, et al. 1999. Osteoclastic responses to various calcium phosphates in cell cultures. J Biomed Mater Res 47:424-433.
69. Drezner MK. 2002. Phosphorus homeostasis and related disorders. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. 2nd ed. San Diego: Academic Press. pp. 321-338.
70. Ecarot B, Glorieux FH, Desbarats M, et al. 1992. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J Bone Miner Res 7:215-220.
71. Econs MJ, Drezner MK. 1994. Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med 330:1679-1681.
72. Eicher EM, Southard JL, Scriver CR, et al. 1976. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA 73:4667-4671.
73. El-Ghannam A. 2005. Bone reconstruction: from bioceramics to tissue engineering. Expert Rev Med Devices 2:87-101.
74. Engstrom C, Linde A, Magnusson BC. 1977. Odontoblast metabolism in rats deficient in vitamin D and calcium I: A histochemical survey. J Oral Pathol 6:359-366.
75. Engstrom C, Jontell M, Linde A. 1978. Odontoblast metabolism in rats deficient in vitamin D and calcium. III. Protein synthesis in vitro. J Oral Pathol 7:227-235.
76. Erben RG, Mayer D, Weber K, et al. 2005. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res 20:1149-1160.
77. Esposito M, Grusovin MG, Coulthard P, et al. 2005. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. Cochrane Database Syst Rev 4:CD003875.
78. Farrow EG, Davis SI, Ward LM, et al. 2007. The role of DMP1 in autosomal recessive hypophosphatemic rickets. J Musculoskelet Neuronal Interact 7:310-312.
79. Fatherazi S, Presland R, Dunn D, et al. 2006.Regulation of osteopontin gene transcription by inorganic phosphate. Proceedinds of ASBMR Twenty-Eighth Annual Meeting; Philadelphia, PA, USA.
80. Fedarko NS, Jain A, Karadag A, et al. 2004. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 18:734-736.
81. Fedde KN, Blair L, Silverstein J, et al. 1999. Alkaline phosphatase knockout mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 14:2015-2026.
82. Feng JQ, Ward LM, Liu S, et al. 2006. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315.
83. Ferrari SL, Bonjour JP, Rizzoli R. 2005. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519-1524.
84. Fisher LW, Fedarko NS. 2003. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44(Suppl 1):33-40.
85. Fleisch H, Bisaz S. 1962. Mechanism of calcification: inhibitory role of pyrophosphate. Nature 195:911.
86. Fleisch H, Straumann F, Schenk R, et al. 1966. Effect of condensed phosphates on calcification of chick embryo femurs in tissue culture. Am J Physiol 211:821-825.
87. Fong HK, Foster BL, Popowics TE, et al. 2005. The crowning achievement: getting to the root of the problem. J Dent Educ 69:555-570.
88. Foster B, Swanson E, Matsa-Dunn D, et al. 2006a. Phosphate regulates expression of SIBLINGs and MMPs in cementoblasts. Proceedings of Hiroshima Conference on Education and Science in Dentistry.43-49.
89. Foster BL, Nociti FH Jr, Swanson EC, et al. 2005. Regulation of SIBLING family genes by phosphate in cementoblasts. Alberta, Canada: Banff Centre.
90. Foster BL, Nociti FH Jr, Swanson EC, et al. 2006b. Regulation of cementoblast gene expression by inorganic phosphate, in vitro. Calcif Tissue Int 78:103-112.
91. Foster BL, Popowics TE, Fong HK, et al. 2007. Advances in defining regulators of cementum development and periodontal regeneration. Curr Top Dev Biol 78:47-126.
92. Francis M, Fogelman I. 1987. 99mTc-diphosphonate uptake mechanisms on bone. In: Fogelman I, editor. Bone scanning in clinical practice. London: Springer. pp. 1-6.
93. Francis MJ, Lees RL, Trujillo E, et al. 2002. ATPase pumps in osteoclasts and osteoblasts. Int J Biochem Cell Biol 34:459-476.
94. Fretz JA, Zella LA, Kim S, et al. 2007. 1,25-Dihydroxyvitamin D3 induces expression of the Wnt signaling coregulator LRP5 via regulatory elements located significantly downstream of the gene's transcriptional start site. J Steroid Biochem Mol Biol 103:440-445.
95. Fu Q, Jilka RL, Manolagas SC, et al. 2002. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875.
96. Fudge NJ, Kovacs CS. 2004. Physiological studies in heterozygous calcium sensing receptor (CaSR) geneablated mice confirm that the CaSR regulates calcitonin release in vivo. BMC Physiol 4:5.
97. Fujita T, Izumo N, Fukuyama R, et al. 2001. Phosphate provides an extracellular signal that drives nuclear export of Runx2/Cbfa1 in bone cells. Biochem Biophys Res Commun 280:348-352.
98. Garg AK. 1999. Grafting Materials in Repair and Restoration. In: Lynch SE, Genco RJ, Marx RE, editors. Tissue engineering: applications in maxillofacial surgery and periodontics Chicago: Quintessence. pp.83-101.
99. Gaur T, Lengner CJ, Hovhannisyan H, et al. 2005. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.
100. Geesink RG, de Groot K, Klein CP. 1987. Chemical implant fixation using hydroxyl-apatite coatings. The development of a human total hip prosthesis for chemical fixation to bone using hydroxyl-apatite coatings on titanium substrates. Clin Orthop Relat Res 225:147-170.
101. George A, Gui J, Jenkins NA, et al. 1994. In situ localization and chromosomal mapping of the AG1 (Dmp1) gene. J Histochem Cytochem 42:1527-1531.
102. Gestrelius S, Lyngstadaas SP, Hammarstrom L. 2000. Emdogain - periodontal regeneration based on biomimicry. Clin Oral Investig 4:120-125.
103. Giannobile WV, Somerman MJ. 2003. Growth and amelogenin-like factors in periodontal wound healing. A systematic review. Ann Periodontol 8:193-204.
104. Glass DA II, Bialek P, Ahn JD, et al. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
105. Goding JW, Terkeltaub R, Maurice M, et al. 1998. Ecto-phosphodiesterase/ pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunol Rev 161:11-26.
106. Goldblatt H, Soames KN. 1923. A study of rats on a normal diet irradiated daily by mercury vapor quartz lamp or kept in darkness. Biochem J 17:294-297.
107. Gomes MF, Camargo AM, Sampaio TA, et al. 2002. Oral manifestations of Albright hereditary osteodystrophy: a case report. Rev Hosp Clin Fac Med Sao Paulo 57:161-166.
108. Gowen LC, Petersen DN, Mansolf AL, et al. 2003. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007.
109. Groeneveld MC, Everts V, Beertsen W. 1995. Alkaline phosphatase activity in the periodontal ligament and gingiva of the rat molar: its relation to cementum formation. J Dent Res 74:1374-1381.
110. Groeneveld MC, Van den Bos T, Everts V, et al. 1996. Cell-bound and extracellular matrix-associated alkaline phosphatase activity in rat periodontal ligament. Experimental Oral Biology Group. J Periodontal Res 31:73-79.
111. Guicheux J, Palmer G, Shukunami C, et al. 2000. A novel in vitro culture system for analysis of functional role of phosphate transport in endochondral ossification. Bone 27:69-74.
112. Gunn IR, Gaffney D. 2004. Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem 41(Part 6):441-458.
113. Guo R, Rowe PS, Liu S, et al. 2002. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 297:38-45.
114. Gupta A, Guo XL, Alvarez UM, et al. 1997. Regulation of sodium-dependent phosphate transport in osteoclasts. J Clin Invest 100:538-549.
115. Gurley KA, Chen H, Guenther C, et al. 2006a. Mineral Formation in Joints Caused by Complete or Joint-Specific Loss of ANK Function. J Bone Miner Res 21:1238-1247.
116. Gurley KA, Reimer RJ, Kingsley DM. 2006b. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet 79:1017-1029.
117. Hacchou Y, Uematsu T, Ueda O, et al. 2007. Inorganic polyphosphate: a possible stimulant of bone formation. J Dent Res 86:893-897.
118. Hak DJ. 2007. The use of osteoconductive bone graft substitutes in orthopaedic trauma. J Am Acad Orthop Surg 15:525-536.
119. Harant H, Andrew PJ, Reddy GS, et al. 1997. 1alpha,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur J Biochem 250:63-71.
120. Harmey D, Hessle L, Narisawa S, et al. 2004. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164:1199-1209.
121. Haussler MR. 1986. Vitamin D receptors: nature and function. Annu Rev Nutr 6:527-562.
122. Hayashibara T, Komura T, Sobue S, et al. 2000. Tooth eruption in a patient with craniometaphyseal dysplasia: case report. J Oral Pathol Med 29:460-462.
123. Hayashibara T, Hiraga T, Sugita A, et al. 2007. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 22:1743-1751.
124. He G, Dahl T, Veis A, et al. 2003. Dentin matrix protein 1 initiates hydroxyapatite formation in vitro. Connect Tissue Res 44(Suppl 1):240-245.
125. Heinonen JK. 2001. Biological role of inorganic pyrophosphate. Norwell: Kluwer Academic Publishers.
126. Helfrich MH, Hocking LJ. 2008. Genetics and aetiology of Pagetic disorders of bone. Arch Biochem Biophys 473:172-182.
127. Henderson JE, Kremer R, Rhim JS, et al. 1992. Identification and functional characterization of adenylate cyclase-linked receptors for parathyroid hormone-like peptides on immortalized human keratinocytes. Endocrinology 130:449-457.
128. Henry HL, Norman AW. 1974. Studies on calciferol metabolism. IX. Renal 25-hydroxy-vitamin D3-1 hydroxylase. Involvement of cytochrome P-450 and other properties. J Biol Chem 249:7529-7535.
129. Herford AS, Boyne PJ. 2008. Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2). J Oral Maxillofac Surg 66:616-624.
130. Hesse M, Frohlich LF, Zeitz U, et al. 2007. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 26:75-84.
131. Hessle L, Johnson KA, Anderson HC, et al. 2002. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99:9445-9449.
132. Ho AM, Johnson MD, Kingsley DM. 2000. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289:265-270.
133. Hoenderop JG, Nilius B, Bindels RJ. 2005. Calcium absorption across epithelia. Physiol Rev 85:373-422.
134. Hollinger JO, Hart CE, Hirsch SN, et al. 2008. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am 90(Suppl 1):48-54.
135. Houston B, Paton IR, Burt DW, et al. 2002. Chromosomal localization of the chicken and mammalian orthologues of the orphan phosphatase PHOSPHO1 gene. Anim Genet 33:451-454.
136. Houston B, Stewart AJ, Farquharson C. 2004. PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage. Bone 34:629-637.
137. Hsieh JC, Kodjabachian L, Rebbert ML, et al. 1999. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398:431-436.
138. Hu B, Nadiri A, Kuchler-Bopp S, et al. 2006. Tissue engineering of tooth crown, root, and periodontium. Tissue Eng 12:2069-2075.
139. HYP_Consortium. 1995. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130-136.
140. Ito M, Matsuka N, Izuka M, et al. 2005. Characterization of inorganic phosphate transport in osteoclast-like cells. Am J Physiol Cell Physiol 288:C921-C931.
141. Ito M, Haito S, Furumoto M, et al. 2007. Unique uptake and efflux systems of inorganic phosphate in osteoclast-like cells. Am J Physiol Cell Physiol 292:C526-C534.
142. Jarvinen E, Salazar-Ciudad I, Birchmeier W, et al. 2006. Continuous tooth generation in mouse is induced by activated epithelial Wnt/beta-catenin signaling. Proc Natl Acad Sci USA 103:18627-18632.
143. Jernvall J, Thesleff I. 2000. Reiterative signaling and patterning during mammalian tooth morphogenesis. Mech Dev 92:19-29.
144. Jilka RL. 2007. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446.
145. Johnson K, Pritzker K, Goding J, et al. 2001. The nucleoside triphosphate pyrophosphohydrolase isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles. J Rheumatol 28:2681-2691.
146. Johnson K, Goding J, Van Etten D, et al. 2003. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 18:994-1004.
147. Johnson KA, Hessle L, Vaingankar S, et al. 2000. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 279:R1365-1377.
148. Jüppner H, Abou-Samra AB, Freeman M, et al. 1991. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026.
149. Kanatani M, Sugimoto T, Kano J, et al. 2003. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol 196:180-189.
150. Kavanagh KL, Guo K, Dunford JE, et al. 2006. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829-7834.
151. Kavanaugh MP, Kabat D. 1996. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int 49:959-963.
152. Kawazoe Y, Shiba T, Nakamura R, et al. 2004. Induction of calcification in MC3T3-E1 cells by inorganic polyphosphate. J Dent Res 83:613-618.
153. Kawazoe Y, Katoh S, Onodera Y, et al. 2008. Activation of the FGF signaling pathway and subsequent induction of mesenchymal stem cell differentiation by inorganic polyphosphate. Int J Biol Sci 4:37-47.
154. Kitahara Y, Suda N, Kuroda T, et al. 2002. Disturbed tooth development in parathyroid hormone-related protein (PTHrP)-gene knockout mice. Bone 30:48-56.
155. Kokubo T, Kim HM, Kawashita M. 2003. Novel bioactive materials with different mechanical properties. Biomaterials 24:2161-2175.
156. Kolek OI, Hines ER, Jones MD, et al. 2005. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289:G1036-G1042.
157. Kondo H, Guo J, Bringhurst FR. 2002. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormonerelated protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res 17:1667-1679.
158. Kumar R. 2002. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens 11:547-553.
159. Kumar R, Haugen JD, Penniston JT. 1993. Molecular cloning of a plasma membrane calcium pump from human osteoblasts. J Bone Miner Res 8:505-513.
160. Kuro-o M, Matsumura Y, Aizawa H, et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51.
161. Kurosu H, Ogawa Y, Miyoshi M, et al. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120-6123.
162. Kuru B, Yilmaz S, Argin K, et al. 2006. Enamel matrix derivative alone or in combination with a bioactive glass in wide intrabony defects. Clin Oral Investig 10:227-234.
163. Langer R, Vacanti JP. 1993. Tissue Engineering. Science 260:920-926.
164. Lanske B, Karaplis AC, Lee K, et al. 1996. PTH/PTHrP receptor in early development and Indian hedgehogregulated bone growth. Science 273:663-666.
165. Lanza R, Langer R, Vacanti JP. 2007. Principles of tissue engineering. 3rd ed. San Diego: Academic Press.
166. Larsson T, Nisbeth U, Ljunggren O, et al. 2003. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279.
167. Larsson T, Marsell R, Schipani E, et al. 2004. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094.
168. Laurikkala J, Kassai Y, Pakkasjarvi L, et al. 2003. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Dev Biol 264:91-105.
169. Le Guehennec L, Soueidan A, Layrolle P, et al. 2007. Surface treatments of titanium dental implants for rapid osseointegration. Dent Mater 23:844-854.
170. Leeuwenburgh SC, Wolke JG, Siebers MC, et al. 2006. In vitro and in vivo reactivity of porous, electrosprayed calcium phosphate coatings. Biomaterials 27:3368-3378.
171. Levi M, Lotscher M, Sorribas V, et al. 1994. Cellular mechanisms of acute and chronic adaptation of rat renal P(i) transporter to alterations in dietary P(i). Am J Physiol 267(5 Part 2):F900-F908.
172. Leyhausen G, Lorenz B, Zhu H, et al. 1998. Inorganic polyphosphate in human osteoblast-like cells. J Bone Miner Res 13:803-812.
173. Li J, Mashiba T, Burr DB. 2001. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281-286.
174. Li X, Liu P, Liu W, et al. 2005. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945-952.
175. Li X, Yang HY, Giachelli CM. 2006. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98:905-912.
176. Ling Y, Rios HF, Myers ER, et al. 2005. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 20:2169-2177.
177. Liu S, Quarles LD. 2007. How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637-1647.
178. Liu S, Guo R, Simpson LG, et al. 2003. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426.
179. Liu S, Brown TA, Zhou J, et al. 2005. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16:1645-1653.
180. Liu S, Zhou J, Tang W, et al. 2006. Pathogenic Role of FGF23 in Hyp Mice. Am J Physiol Endocrinol Metab 291:E38-E49.
181. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. 2006. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250.
182. Lu C, Huang S, Miclau T, et al. 2004. Mepe is expressed during skeletal development and regeneration. Histochem Cell Biol 121:493-499.
183. Lundgren T, Stenport V, Wetter A, et al. 1998. Parathyroid hormone (1-34) receptor-binding and second-messenger response in rat incisor odontoblasts. Calcif Tissue Int 62:255-259.
184. Lundquist P. 2002. Odontoblast phosphate and calcium transport in dentinogenesis. Swed Dent J Suppl 154:1-52.
185. Lundquist P, Ritchie HH, Moore K, et al. 2002. Phosphate and calcium uptake by rat odontoblast-like MRPC-1 cells concomitant with mineralization. J Bone Miner Res 17:1801-1813.
186. MacDougall M, Simmons D, Gu TT, Dong J. 2002. MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. Connect Tissue Res 43:320-330.
187. Mansfield K, Rajpurohit R, Shapiro IM. 1999. Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. J Cell Physiol 179:276-286.
188. Mansfield K, Teixeira CC, Adams CS, et al. 2001. Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. Bone 28:1-8.
189. Mansfield K, Pucci B, Adams CS, Shapiro IM. 2003. Induction of apoptosis in skeletal tissues: phosphate-mediated chick chondrocyte apoptosis is calcium dependent. Calcif Tissue Int 73:161-172.
190. Martin A, David V, Laurence JS, et al. 2008. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757-1772.
191. Marx RE, Sawatari Y, Fortin M, et al. 2005. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575.
192. Mashiba T, Hirano T, Turner CH, et al. 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620.
193. Mashiba T, Turner CH, Hirano T, et al. 2001. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531.
194. Masuyama R, Stockmans I, Torrekens S, et al. 2006. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116:3150-3159.
195. Matalova E, Fleischmannova J, Sharpe PT, et al. 2008. Tooth agenesis: from molecular genetics to molecular dentistry. J Dent Res 87:617-623.
196. Matsumoto T, Okazaki M, Nakahira A, et al. 2007. Modification of apatite materials for bone tissue engineering and drug delivery carriers. Curr Med Chem 14:2726-2733.
197. Meleti Z, Shapiro IM, Adams CS. 2000. Inorganic phosphate induces apoptosis of osteoblast-like cells in culture. Bone 27:359-366.
198. Mellanby E. 1921. Experimental rickets. Spec Rep Ser Med Res Council SRS61:4.
199. Memon F, El-Abbadi M, Nakatani T, et al. 2008. Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? Kidney Int 74:566-570.
200. Mengel R, Soffner M, Flores-de-Jacoby L. 2003. Bioabsorbable membrane and bioactive glass in the treatment of intrabony defects in patients with generalized aggressive periodontitis: results of a 12-month clinical and radiological study. J Periodontol 74:899-908.
201. Mengel R, Schreiber D, Flores-de-Jacoby L. 2006. Bioabsorbable membrane and bioactive glass in the treatment of intrabony defects in patients with generalized aggressive periodontitis: results of a 5-year clinical and radiological study. J Periodontol 77:1781-1787.
202. Meszaros JG, Karin NJ. 1993. Osteoblasts express the PMCA1b isoform of the plasma membrane Ca(2+)-ATPase. J Bone Miner Res 8:1235-1240.
203. Meyer JL. 1984. Can biological calcification occur in the presence of pyrophosphate? Archives of biochemistry and biophysics 231:1-8.
204. Miao D, Bai X, Panda DK, Karaplis AC, Goltzman D, McKee MD. 2004. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone 34:638-647.
205. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. 2005. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83-93.
206. Miliauskaite A, Selimovic D, Hannig M. 2007. Successful management of aggressive periodontitis by regenerative therapy: a 3-year follow-up case report. J Periodontol 78:2043-2050.
207. Millan JL. 2006. Mammalian alkaline phosphatases. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. 322 p.
208. Millan JL, Narisawa S, Lemire I, et al. 2008. Enzyme Replacement Therapy for Murine Hypophosphatasia. J Bone Miner Res 23:777-787.
209. Mitnick PD, Goldfarb S, Slatopolsky E, et al. 1980. Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med 92:482-487.
210. Mozar A, Haren N, Chasseraud M, et al. 2008. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 215:47-54.
211. Mulkins MA, Manolagas SC, Deftos LJ, et al. 1983. 1,25-Dihydroxyvitamin D3 increases bone alkaline phosphatase isoenzyme levels in human osteogenic sarcoma cells. J Biol Chem 258:6219-6225.
212. Murayama T, Iwatsubo R, Akiyama S, et al. 2000. Familial hypophosphatemic vitamin D-resistant rickets: dental findings and histologic study of teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:310-316.
213. Murer H, Forster I, Hilfiker H, et al. 1998. Cellular/molecular control of renal Na/Pi-cotransport. Kidney Int Suppl 65:S2-S10.
214. Murer H, Forster I, Hernando N, et al. 1999. Posttranscriptional regulation of the proximal tubule NaPi-II transporter in response to PTH and dietary P(i). Am J Physiol 277(5 Part 2):F676-F684.
215. Murshed M, Harmey D, Millan JL, et al. 2005. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19:1093-1104.
216. Nadiri A, Kuchler-Bopp S, Haikel Y, et al. 2004. Immunolocalization of BMP-2/-4, FGF-4, and WNT10b in the developing mouse first lower molar. J Histochem Cytochem 52:103-112.
217. Nagpal S, Na S, Rathnachalam R. 2005. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662-687.
218. Nakano Y, Beertsen W, van den Bos T, et al. 2004. Site-specific localization of two distinct phosphatases along the osteoblast plasma membrane: tissue non-specific alkaline phosphatase and plasma membrane calcium ATPase. Bone 35:1077-1085.
219. Nakano Y, Kawamoto T, Oda K, et al. 2003. Alkaline and acid phosphatases in bone cells serve as phosphohydrolases at physiological pH in vivo: a histochemical implication. Connect Tissue Res 44 Suppl 1:219-222.
220. Nakao K, Morita R, Saji Y, et al. 2007. The development of a bioengineered organ germ method. Nat Methods 4:227-230.
221. Nampei A, Hashimoto J, Hayashida K, et al. 2004. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22:176-184.
222. Nanci A. 2003. Development of the tooth and its supporting tissues. In: Nanci A, editor. Ten Cate's oral histology: development, structure, and function. 6th ed. St. Louis: Mosby.
223. Narayanan K, Srinivas R, Ramachandran A, et al. 2001. Differentiation of embryonic mesenchymal cells to odontoblast-like cells by overexpression of dentin matrix protein 1. Proc Natl Acad Sci USA 98:4516-4521.
224. Narayanan K, Ramachandran A, Hao J, et al. 2002. Transcriptional regulation of dentin matrix protein 1 (DMP1) by AP-1 (c-fos/c-jun) factors. Connect Tissue Res 43:365-371.
225. Narayanan K, Ramachandran A, Hao J, et al. 2003. Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca21 store. J Biol Chem 278:17500-17508.
226. Narisawa S, Frohlander N, Millan JL. 1997. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn 208:432-446.
227. Nashiki K, Taketani Y, Takeichi T, et al. 2005. Role of membrane microdomains in PTH-mediated down-regulation of NaPi-IIa in opossum kidney cells. Kidney Int 68:1137-1147.
228. Nery EB, LeGeros RZ, Lynch KL, Lee K. 1992. Tissue response to biphasic calcium phosphate ceramic with different ratios of HA/beta TCP in periodontal osseous defects. J Periodontol 63:729-735.
229. Netter P, Bardin T, Bianchi A, et al. 2004. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine 71:365-368.
230. Netuveli GS, Sheiham A. 2004. A systematic review of the effectiveness of anticalculus dentifrices. Oral Health Prev Dent 2:49-58.
231. Niall HD, Keutmann H, Sauer R, et al. 1970. The amino acid sequence of bovine parathyroid hormone I. Hoppe Seylers Z Physiol Chem 351:1586-1588.
232. Nielsen LB, Pedersen FS, Pedersen L. 2001. Expression of type III sodium-dependent phosphate transporters/retroviral receptors mRNAs during osteoblast differentiation. Bone 28:160-166.
233. Nociti FH Jr, Berry JE, Foster BL, et al. 2002. Cementum: a phosphate-sensitive tissue. J Dent Res 81:817-821.
234. Nurnberg P, Thiele H, Chandler D, et al. 2001. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 28:37-41.
235. Oftebro H, Saarem K, Bjorkhem I, et al. 1981. Side chain hydroxylation of C27-steroids and vitamin D3 by a cytochrome P-450 enzyme system isolated from human liver mitochondria. J Lipid Res 22:1254-1264.
236. Ogawa T, Onishi T, Hayashibara T, et al. 2006. Dentinal defects in Hyp mice not caused by hypophosphatemia alone. Arch Oral Biol 51:58-63.
237. Ogbureke KU, Fisher LW. 2007. SIBLING expression patterns in duct epithelia reflect the degree of metabolic activity. J Histochem Cytochem 55:403-409.
238. Ohazama A, Modino SA, Miletich I, et al. 2004. Stem-cell-based tissue engineering of murine teeth. J Dent Res 83:518-522.
239. Ohshima H, Nakasone N, Hashimoto E, et al. 2005. The eternal tooth germ is formed at the apical end of continuously growing teeth. Arch Oral Biol 50:153-157.
240. Okawa A, Nakamura I, Goto S, et al. 1998. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 19:271-273.
241. Onishi T, Ogawa T, Hayashibara T, Hoshino T, Okawa R, Ooshima T. 2005. Hyper-expression of osteocalcin mRNA in odontoblasts of Hyp mice. J Dent Res 84:84-88.
242. Onishi T, Okawa R, Ogawa T, et al. 2007. Phex mutation causes the reduction of npt2b mRNA in teeth. J Dent Res 86:158-162.
243. Onishi T, Umemura S, Shintani S, et al. 2008. Phex mutation causes overexpression of FGF23 in teeth. Arch Oral Biol 53:99-104.
244. Ornitz DM, Xu J, Colvin JS, et al. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271:15292-15297.
245. Ouyang H, McCauley LK, Berry JE, et al. 2000. Response of immortalized murine cementoblasts/periodontal ligament cells to parathyroid hormone and parathyroid hormone-related protein in vitro. Arch Oral Biol 45:293-303.
246. Palmer G, Zhao J, Bonjour J, et al. 1999. In vivo expression of transcripts encoding the Glvr-1 phosphate transporter/retrovirus receptor during bone development. Bone 24:1-7.
247. Panda DK, Miao D, Tremblay ML, et al. 2001. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98:7498-7503.
248. Papaccio G, Graziano A, d'Aquino R, et al. 2006. Long-term cryopreservation of dental pulp stem cells (SBP-DPSCs) and their differentiated osteoblasts: a cell source for tissue repair. J Cell Physiol 208:319-325.
249. Papagerakis P, MacDougall M, Berdal A. 2002. Differential epithelial and mesenchymal regulation of tooth-specific matrix proteins expression by 1,25-dihydroxyvitamin D3 in vivo. Connect Tissue Res 43:372-375.
250. Park JS, Suh JJ, Choi SH, et al. 2001. Effects of pretreatment clinical parameters on bioactive glass implantation in intrabony periodontal defects. J Periodontol 72:730-740.
251. Parker CC. 2005. The role of bisphosphonates in the treatment of prostate cancer. BJU Int 95:935-938.
252. Pavlakis N, Schmidt R, Stockler M. 2005. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474.
253. Pendleton A, Johnson MD, Hughes A, et al. 2002. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 71:933-940.
254. Peng JB, Chen XZ, Berger UV, et al. 1999. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem 274:22739-22746.
255. Perwad F, Azam N, Zhang MY, et al. 2005. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358-5364.
256. Pettway GJ, Meganck JA, Koh AJ, et al. 2008. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806-818.
257. Pispa J, Thesleff I. 2003. Mechanisms of ectodermal organogenesis. Dev Biol 262:195-205.
258. Poole KE, Reeve J. 2005. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 5:612-617.
259. Popowics T, Foster BL, Swanson EC, et al. 2005. Defining the roots of cementum formation. Cells Tissues Organs 181:248-257.
260. Prasad V, Okunade GW, Miller ML, et al. 2004. Phenotypes of SERCA and PMCA knockout mice. Biochem Biophys Res Commun 322:1192-1203.
261. Prince MJ, Schaeffer PC, Goldsmith RS, et al. 1982. Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25- dihydroxycholecalciferol concentrations. Ann Intern Med 96:586-591.
262. Prufer K, Racz A, Lin GC, et al. 2000. Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J Biol Chem 275:41114-41123.
263. Qin C, Brunn JC, Cook RG, et al. 2003. Evidence for the proteolytic processing of dentin matrix protein 1. Identification and characterization of processed fragments and cleavage sites. J Biol Chem 278:34700-34708.
264. Qin C, Baba O, Butler WT. 2004. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15:126-136.
265. Quarles LD. 2003. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1-E9.
266. Rasmussen H, Tenenhouse HS. 1995. Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw Hill. 3717 p.
267. Ravera S, Virkki LV, Murer H, et al. 2007. Deciphering PiT transport kinetics and substrate specificity using electrophysiology and flux measurements. Am J Physiol Cell Physiol 293:C606-C620.
268. Razzaque MS, St-Arnaud R, Taguchi T, et al. 2005. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 20:2032-2035.
269. Reginster JY, Felsenberg D, Cooper C, et al. 2006. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 17:159-166.
270. Reichenberger E, Tiziani V, Watanabe S, et al. 2001. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 68:1321-1326.
271. Reid IR, Brown JP, Burckhardt P, et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661.
272. Renkema KY, Alexander RT, Bindels RJ, et al. 2008. Calcium and phosphate homeostasis: concerted interplay of new regulators. Ann Med 40:82-91.
273. Reynolds MA, Aichelmann-Reidy ME, Branch-Mays GL, et al. 2003. The efficacy of bone replacement grafts in the treatment of periodontal osseous defects. A systematic review. Ann Periodontol 8:227-265.
274. Riccardi D, Park J, Lee WS, et al. 1995. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 92:131-135.
275. Riminucci M, Collins MT, Fedarko NS, et al. 2003. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692.
276. Ritchie HH, Park H, Liu J, et al. 2004. Effects of dexamethasone, vitamin A and vitamin D3 on DSP-PP mRNA expression in rat tooth organ culture. Biochim Biophys Acta 1679:263-271.
277. Roberts S, Narisawa S, Harmey D, et al. 2007. Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. J Bone Miner Res 22:617-627.
278. Roberts SJ, Stewart AJ, Sadler PJ, et al. 2004. Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities. Biochem J 382 (Part 1):59-65.
279. Roberts SJ, Stewart AJ, Schmid R, et al. 2005. Probing the substrate specificities of human PHOSPHO1 and PHOSPHO2. Biochim Biophys Acta 1752:73-82.
280. Rodan GA, Reszka AA. 2003. Osteoporosis and bisphosphonates. J Bone Joint Surg Am 85-A Suppl 3:8-12.
281. Rogers MJ. 2003. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643-2658.
282. Rondeau JM, Bitsch F, Bourgier E, et al. 2006. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Chem Med Chem 1:267-273.
283. Rosenblatt M, Segre GV, Tregear GW, et al. 1978. Human parathyroid hormone: synthesis and chemical, biological, and immunological evaluation of the carboxyl-terminal region. Endocrinology 103:978-984.
284. Rowe PS. 2004. The wrickkened pathways of FGF23, MEPE, and PHEX. Crit Rev Oral Biol Med 15:264-281.
285. Rowe PS, de Zoysa PA, Dong R, et al. 2000. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68.
286. Rowe PS, Kumagai Y, Gutierrez G, et al. 2004. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319.
287. Roy DM, Linnehan SK. 1974. Hydroxyapatite formed from coral skeletal carbonate by hydrothermal exchange. Nature 247:220-222.
288. Roy S, Martel J, Ma S, Tenenhouse HS. 1994. Increased renal 25-hydroxyvitamin D3-24-hydroxylase messenger ribonucleic acid and immunoreactive protein in phosphate-deprived Hyp mice: a mechanism for accelerated 1,25-dihydroxyvitamin D3 catabolism in X-linked hypophosphatemic rickets. Endocrinology 134:1761-1767.
289. Ruchon AF, Tenenhouse HS, Marcinkiewicz M, et al. 2000. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J Bone Miner Res 15:1440-1450.
290. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534.
291. Russell J, Bar A, Sherwood LM, et al. 1993. Interaction between calcium and 1,25-dihydroxyvitamin D3 in the regulation of preproparathyroid hormone and vitamin D receptor messenger ribonucleic acid in avian parathyroids. Endocrinology 132:2639-2644.
292. Russell RG. 2007. Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150-S162.
293. Rutherford RB, Foster BL, Bammler T, et al. 2006. Extracellular phosphate alters cementoblast gene expression. J Dent Res 85:505-509.
294. Rutsch F, Terkeltaub R. 2005. Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. Joint Bone Spine 72:110-118.
295. Rutsch F, Schauerte P, Kalhoff H, et al. 2000. Low levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a boy with idiopathic infantile arterial calcification. Acta Paediatr 89:1265-1269.
296. Rutsch F, Vaingankar S, Johnson K, et al. 2001. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 158:543-554.
297. Ryan LM. 2001. The ank gene story. Arthritis Res 3:77-79.
298. Santini D, Vespasiani Gentilucci U, et al. 2003. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14:1468-1476.
299. Saygin NE, Giannobile WV, Somerman MJ. 2000. Molecular and cell biology of cementum. Periodontology 24:73-98.
300. Schiavi SC. 2006. Fibroblast growth factor 23: the making of a hormone. Kidney Int 69:425-427.
301. Schiavi SC, Kumar R. 2004. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65:1-14.
302. Segawa H, Kawakami E, Kaneko I, et al. 2003. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch 446:585-592.
303. Sharma CG, Pradeep AR. 2007. Localized attachment loss in Pendred syndrome: incidental? J Periodontol 78:948-954.
304. Shen Q, Christakos S. 2005. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem 280:40589-40598.
305. Shields ED, Scriver CR, Reade T, et al. 1990. X-linked hypophosphatemia: the mutant gene is expressed in teeth as well as in kidney. Am J Hum Genet 46:434-442.
306. Shimada T, Mizutani S, Muto T, et al. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505.
307. Shimada T, Muto T, Urakawa I, et al. 2002. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182.
308. Shimada T, Kakitani M, Yamazaki Y, et al. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568.
309. Siris ES, Lyles KW, Singer FR, et al. 2006. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 21 (Suppl 2):P94-P98.
310. Sirohi B, Powles R. 2004. Multiple myeloma. Lancet 363:875-887.
311. Sitara D, Razzaque MS, Hesse M, et al. 2004. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432.
312. Sitara D, Razzaque MS, St-Arnaud R, et al. 2006. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169:2161-2170.
313. Soballe K, Hansen ES, Brockstedt-Rasmussen H, et al. 1991. Gap healing enhanced by hydroxyapatite coating in dogs. Clin Orthop Relat Res 272:300-307.
314. Soballe K, Mouzin OR, Kidder LA, et al. 2003. The effects of hydroxyapatite coating and bone allograft on fixation of loaded experimental primary and revision implants. Acta Orthop Scand 74:239-247.
315. Sofaer JA, Southam JC. 1982. Naturally-occurring exposure of the dental pulp in mice with inherited hypophosphataemia. Arch Oral Biol 27:701-703.
316. Stains JP, Weber JA, Gay CV. 2002. Expression of Na(+)/Ca(2+) exchanger isoforms (NCX1 and NCX3) and plasma membrane Ca(2+) ATPase during osteoblast differentiation. J Cell Biochem 84:625-635.
317. Stewart AJ, Schmid R, Blindauer CA, et al. 2003. Comparative modelling of human PHOSPHO1 reveals a new group of phosphatases within the haloacid dehalogenase superfamily. Protein Eng 16:889-895.
318. Stewart AJ, Roberts SJ, Seawright E, et al. 2006. The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization. Bone 39:1000-1007.
319. Storm T, Thamsborg G, Steiniche T, et al. 1990. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
320. Suda T, Takahashi N, Udagawa N, et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
321. Sutton AL, MacDonald PN. 2003. Vitamin D: more than a "bone-a-fide" hormone. Mol Endocrinol 17:777-791.
322. Suva LJ, Winslow GA, Wettenhall RE, et al. 1987. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893-896.
323. Suzuki A, Palmer G, Bonjour JP, et al. 2000. Stimulation of sodium-dependent phosphate transport and signaling mechanisms induced by basic fibroblast growth factor in MC3T3-E1 osteoblast-like cells. J Bone Miner Res 15:95-102.
324. Suzuki A, Palmer G, Bonjour JP, et al. 2001. Stimulation of sodium-dependent inorganic phosphate transport by activation of Gi/o-protein-coupled receptors by epinephrine in MC3T3-E1 osteoblast-like cells. Bone 28:589-594.
325. Suzuki A, Ghayor C, Guicheux J, et al. 2006. Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res 21:674-683.
326. Suzuki H, Amizuka N, Oda K, et al. 2008. Involvement of the klotho protein in dentin formation and mineralization. Anat Rec (Hoboken) 291:183-190.
327. Sweet HO, Green MC. 1981. Progressive ankylosis, a new skeletal mutation in the mouse. J Hered 72:87-93.
328. Takeyama S, Yoshimura Y, Deyama Y, et al. 2001. Phosphate decreases osteoclastogenesis in coculture of osteoblast and bone marrow. Biochem Biophys Res Commun 282:798-802.
329. Teixeira CC, Mansfield K, Hertkorn C, et al. 2001. Phosphate-induced chondrocyte apoptosis is linked to nitric oxide generation. Am J Physiol Cell Physiol 281:C833-C839.
330. Tenorio D, Hughes FJ. 1996. An immunohistochemical investigation of the expression of parathyroid hormone receptors in rat cementoblasts. Arch Oral Biol 41:299-305.
331. Terkeltaub RA. 2001. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281:C1-C11.
332. Termine JD, Peckauskas RA, Posner AS. 1970. Calcium phosphate formation in vitro. II. Effects of environment on amorphous-crystalline transformation. Arch Biochem Biophys 140:318-325.
333. Thesleff I. 2003. Epithelial-mesenchymal signalling regulating tooth morphogenesis. J Cell Sci 116(Part 9):1647-1648.
334. Thesleff I, Sharpe P. 1997. Signalling networks regulating dental development. Mech Dev 67:111-123.
335. Topaz O, Shurman DL, Bergman R, et al. 2004. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581.
336. Toyosawa S, Shintani S, Fujiwara T, et al. 2001. Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 16:2017-2026.
337. Toyosawa S, Okabayashi K, Komori T, et al. 2004. mRNA expression and protein localization of dentin matrix protein 1 during dental root formation. Bone 34:124-133.
338. Tregear GW, Van Rietschoten J, Greene E, et al. 1973. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 93:1349-1353.
339. Tsukamoto Y, Fukutani S, Shin-Ike T, et al. 1992. Mineralized nodule formation by cultures of human dental pulp-derived fibroblasts. Arch Oral Biol 37:1045-1055.
340. Tummers M, Thesleff I. 2008. Observations on continuously growing roots of the sloth and the K14-Eda transgenic mice indicate that epithelial stem cells can give rise to both the ameloblast and root epithelium cell lineage creating distinct tooth patterns. Evol Dev 10:187-195.
341. Udagawa N, Takahashi N, Akatsu T, et al. 1990. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87:7260-7264.
342. Urakawa I, Yamazaki Y, Shimada T, et al. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774.
343. Vaes BL, Dechering KJ, van Someren EP, et al. 2005. Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 36:803-811.
344. Vaingankar SM, Fitzpatrick TA, Johnson K, et al. 2004. Subcellular targeting and function of osteoblast nucleotide pyrophosphatase phosphodiesterase 1. Am J Physiol Cell Physiol 286:C1177-C1187.
345. van den Bos T, Handoko G, Niehof A, et al. 2005. Cementum and dentin in hypophosphatasia. J Dent Res 84:1021-1025.
346. Wang HL, Cooke J. 2005. Periodontal regeneration techniques for treatment of periodontal diseases. Dent Clin North Am 49:637-659.
347. Warren SM, Nacamuli RK, Song HM, Longaker MT. 2004. Tissue-engineered bone using mesenchymal stem cells and a biodegradable scaffold. J Craniofac Surg 15:34-37.
348. Watts NB, Harris ST, Genant HK, et al. 1990. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
349. Weninger M, Stinson RA, Plenk H Jr, et al. 1989. Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr Scand Suppl 360:154-160.
350. Werner S, Duan DS, de Vries C, et al. 1992. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 12:82-88.
351. White KE, Jonsson KB, Carn G, et al. 2001. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500.
352. White KE, Larsson TM, Econs MJ. 2006. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 27:221-41.
353. WHO. 2003. World Oral Health Report 2003. Noncommunicable Disease Prevention and Health Promotion, Oral Health Programme. Geneza, Switzerland: WHO. 45 p.
354. Whyte MP. 1994. Hypophosphatasia and the role alkaline phosphatase in skeletal mineralization. Endocr Rev 15:439-461.
355. Whyte MP. 2002. Hypophosphatasia Nature's window to alkaline phosphatase in man. In: Bilezikian JP, Raisz LG , Rodan GA, editors. Principles of Bone Biology. 2nd ed. San Diego, CA: Academic Press. pp. 1229-1248.
356. Whyte MP, Valdes R Jr, Ryan LM, et al. 1982. Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr 101:379-386.
357. Whyte MP, McAlister WH, Patton LS, et al. 1984. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. J Pediatr 105:926-933.
358. Whyte MP, Landt M, Ryan LM, et al. 1995. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5′-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest 95:1440-1445.
359. Woo SB, Hande K, Richardson PG. 2005. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102; discussion 199-102.
360. Woo SB, Hellstein JW, Kalmar JR. 2006. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761.
361. Wood J, Bonjean K, Ruetz S, et al. 2002. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061.
362. Wysolmerski JJ, Cormier S, Philbrick WM, et al. 2001. Absence of functional type 1 parathyroid hormone (PTH)/PTH-related protein receptors in humans is associated with abnormal breast development and tooth impaction. J Clin Endocrinol Metab 86:1788-1794.
363. Xiao NM, Zhang YM, Zheng Q, et al. 2004. Klotho is a serum factor related to human aging. Chin Med J (Engl) 117:742-747.
364. Yamamoto T. 2006. Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome. J Bone Miner Metab 24:7-10.
365. Yamamoto T, Imanishi Y, Kinoshita E, et al. 2005. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 23:231-237.
366. Yamaoka M, Uematsu T, Shiba T, et al. 2008. Effect of inorganic polyphosphate in periodontitis in the elderly. Gerodontology 25:10-17.
367. Yamashita T, Yoshioka M, Itoh N. 2000. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494-498.
368. Yamashita T, Konishi M, Miyake A, et al. 2002. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265-28270.
369. Yang W, Kalajzic I, Lu Y, et al. 2004. In vitro and in vivo study on osteocyte-specific mechanical signaling pathways. J Musculoskelet Neuronal Interact 4:386-387.
370. Yasutake J, Shimada T, Urakawa I, et al. 2006.Effects of FGF23 and soluble Klotho on mineralization of MC3T3-E1 osteoblastic cells. Proceedings of Twenty-eighth ASBMR Annual Meeting; Philadelphia, PA, USA.
371. Yates AJ, Oreffo RO, Mayor K, et al. 1991. Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclast formation and decreased activity of mature osteoclasts. J Bone Miner Res 6:473-478.
372. Ye L, MacDougall M, Zhang S, et al. 2004. Deletion of dentin matrix protein-1 leads to a partial failure of maturation of predentin into dentin, hypomineralization, and expanded cavities of pulp and root canal during postnatal tooth development. J Biol Chem 279:19141-19148.
373. Ye L, Mishina Y, Chen D, et al. 2005. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem 280:6197-6203.
374. Ye L, Zhang S, Ke H, et al. 2008. Periodontal breakdown in the dmp1 null mouse model of hypophosphatemic rickets. J Dent Res 87:624-629.
375. Yoon KG, Rutledge SJ, Buenaga RF, et al. 1988. Characterization of the
376. Yoshiko Y, Wang H, Minamizaki T, et al. 2007. Mineralized tissue cells are a principal source of FGF23. Bone 40:1565-1573.
377. Young CS, Terada S, Vacanti JP, et al. 2002. Tissue engineering of complex tooth structures on biodegradable polymer scaffolds. J Dent Res 81:695-700.
378. Yu X, White KE. 2005a. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 16:221-232.
379. Yu X, White KE. 2005b. Fibroblast growth factor 23 and its receptors. Ther Apher Dial 9:308-312.
380. Yu X, Ibrahimi OA, Goetz R, et al. 2005. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146:4647-4656.
381. Yu X, Davis SI, Larsson T, et al. 2006.Regulation of Klotho expression in distal convoluted tubule cells. Proceedings of Twenty-eighth ASBMR Annual Meeting; Philadelphia, PA, USA.
382. Zacherl WA, Pfeiffer HJ, Swancar JR. 1985. The effect of soluble pyrophosphates on dental calculus in adults. J Am Dent Assoc 110:737-738.
383. Zafiropoulos GG, Hoffmann O, Kasaj A, et al. 2007. Treatment of intrabony defects using guided tissue regeneration and autogenous spongiosa alone or combined with hydroxyapatite/beta-tricalcium phosphate bone substitute or bovine-derived xenograft. J Periodontol 78:2216-2225.
384. Zhang H, Somerman MJ, Berg J, et al. 2007a. Dental anomalies in a child with craniometaphysial dysplasia. Pediatr Dent 29:415-419.
385. Zhang X, Rahemtulla FG, MacDougall MJ, et al. 2007b. Vitamin D receptor deficiency affects dentin maturation in mice. Arch Oral Biol 52:1172-1179.
386. Zhao D, Vaziri Sani F, Nilsson J, et al. 2006. Expression of Pit2 sodium-phosphate cotransporter during murine odontogenesis is developmentally regulated. Eur J Oral Sci 114:517-523.
387. Zoidis E, Ghirlanda-Keller C, Gosteli-Peter M, et al. 2004. Regulation of phosphate (Pi) transport and NaPi-III transporter (Pit-1) mRNA in rat osteoblasts. J Endocrinol 181:531-540.